Advances in Urate Excretion and Urate Transporters in Hyperuricemia

doi:10.12114/j.issn.1007-9572.2022.0747

Abstract

Abstract:

Hyperuricemia is a heterogeneous disease caused by dysregulation of the homeostasis of urate production and excretion, which leads to the elevation of blood uric acid beyond the normal range. It has been found that three common genes ABCG2, SLC2A9 and SLC22A12 have a great influence on serum uric acid level in human body. Other urate transporter genes, such as SLC16A9, SLC22A6, SLC22A7, SLC22A8, SLC22A9, SLC22A11, SLC22A13 and ABCC4 also play a crucial role in the regulation of urate levels. This article reviews the urate transporters mentioned above that have been found to be related to the development of hyperuricemia, including uric acid reabsorption transporter and uric acid secretion transporter in kidney, uric acid transporter in intestine, aiming at providing theoretical and data support for future clinical treatment.

Key words: Hyperuricemia, Uric acid, Uric acid transporter, Gene expression, Review

摘要：

高尿酸血症（HUA）是人体内尿酸生成和排泄稳态失调从而导致血清尿酸水平升高超过参考范围的一类异质性疾病。既往研究发现3个常见尿酸转运蛋白基因（ABCG2、SLC2A9和SLC22A12）对人体血清尿酸水平的影响程度较大，其他尿酸相关的转运蛋白基因（如SLC16A9、SLC22A6、SLC22A7、SLC22A8、SLC22A9、SLC22A11、SLC22A13和ABCC4等）也对尿酸水平的调节起着至关重要的作用。本文对上述已发现的与HUA发生和发展相关的尿酸转运蛋白做一综述，主要包括肾脏中的尿酸重吸收转运蛋白和尿酸分泌转运蛋白以及肠道中的尿酸转运蛋白，旨在为今后HUA的临床治疗提供理论和数据支持。

关键词: 高尿酸血症, 尿酸, 尿酸转运蛋白, 基因表达, 综述

XIN Jiadong,ZHOU Jiabao,WU Zhiyuan, et al. Advances in Urate Excretion and Urate Transporters in Hyperuricemia[J]. Chinese General Practice, 2023, 26(15): 1916-1922. DOI: 10.12114/j.issn.1007-9572.2022.0747.
辛家东,周嘉宝,吴志远等. 尿酸排泄及其相关转运蛋白在高尿酸血症中的研究进展[J]. 中国全科医学, 2023, 26(15): 1916-1922. DOI: 10.12114/j.issn.1007-9572.2022.0747.

Figures/Tables 2

References 74

[1]	KANG D H，CHEN W. Uric acid and chronic kidney disease: new understanding of an old problem[J]. Semin Nephrol，2011，31（5）：447-452. DOI：10.1016/j.semnephrol.2011.08.009.
[2]	PETRESKI T，EKART R，HOJS R，et al. Hyperuricemia，the heart，and the kidneys - to treat or not to treat?[J]. Ren Fail，2020，42（1）：978-986. DOI：10.1080/0886022X.2020.1822185.
[3]	TÁTRAI P，ERD F，DÖRNYEI G，et al. Modulation of urate transport by drugs[J]. Pharmaceutics，2021，13（6）：899. DOI：10.3390/pharmaceutics13060899.
[4]	CHEN-XU M，YOKOSE C，RAI S K，et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey，2007-2016[J]. Arthritis Rheumatol，2019，71（6）：991-999. DOI：10.1002/art.40807.
[5]	DEHLIN M，JACOBSSON L，RODDY E. Global epidemiology of gout: prevalence，incidence，treatment patterns and risk factors[J]. Nat Rev Rheumatol，2020，16（7）：380-390. DOI：10.1038/s41584-020-0441-1.
[6]	DALBETH N，MERRIMAN TR，STAMP LK. Gout[J]. Lancet，388（10055）：2039-2052. DOI：10.1016/S0140-6736(16)00346-9.
[7]	SOLTANI Z，RASHEED K，KAPUSTA D R，et al. Potential role of uric acid in metabolic syndrome，hypertension，kidney injury，and cardiovascular diseases: is it time for reappraisal?[J]. Curr Hypertens Rep，2013，15（3）：175-181. DOI：10.1007/s11906-013-0344-5.
[8]	ICHIDA K，MATSUO H，TAKADA T，et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia[J]. Nat Commun，2012，3：764. DOI：10.1038/ncomms1756.
[9]	WANG Z，CUI T，CI X Y，et al. The effect of polymorphism of uric acid transporters on uric acid transport[J]. J Nephrol，2019，32（2）：177-187. DOI：10.1007/s40620-018-0546-7.
[10]	RUIZ A，GAUTSCHI I，SCHILD L，et al. Human mutations in SLC2A9 （Glut9） affect transport capacity for urate[J]. Front Physiol，2018，9：476. DOI：10.3389/fphys.2018.00476.
[11]	MANDAL A K，MERCADO A，FOSTER A，et al. Uricosuric targets of tranilast[J]. Pharmacol Res Perspect，2017，5（2）：e00291. DOI：10.1002/prp2.291.
[12]	ENOMOTO A，KIMURA H，CHAIROUNGDUA A，et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature，2002，417（6887）：447-452. DOI：10.1038/nature742.
[13]	TAN P K，LIU S，GUNIC E，et al. Discovery and characterization of verinurad，a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout[J]. Sci Rep，2017，7（1）：665. DOI：10.1038/s41598-017-00706-7.
[14]	HIGASHINO T，MATSUO H，SAKIYAMA M，et al. Common variant of PDZ domain containing 1 （PDZK1） gene is associated with gout susceptibility: a replication study and meta-analysis in Japanese population[J]. Drug Metab Pharmacokinet，2016，31（6）：464-466. DOI：10.1016/j.dmpk.2016.07.004.
[15]	MISAWA K，HASEGAWA T，MISHIMA E，et al. Contribution of rare variants of the SLC22A12 gene to the missing heritability of serum urate levels[J]. Genetics，2020，214（4）：1079-1090. DOI：10.1534/genetics.119.303006.
[16]	SAKIYAMA M，MATSUO H，SHIMIZU S，et al. The effects of URAT1/SLC22A12 nonfunctional variants，R90H and W258X，on serum uric acid levels and gout/hyperuricemia progression[J]. Sci Rep，2016，6：20148. DOI：10.1038/srep20148.
[17]	SHIN H J，TAKEDA M，ENOMOTO A，et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs[J]. Nephrology （Carlton），2011，16（2）：156-162. DOI：10.1111/j.1440-1797.2010.01368.x.
[18]	XU L，LU L L，GAO J D. Traditional Chinese herbal medicine plays a role in the liver，kidney，and intestine to ameliorate hyperuricemia according to experimental studies[J]. Evid Based Complement Alternat Med，2021，2021：4618352. DOI：10.1155/2021/4618352.
[19]	NOVIKOV A，FU Y L，HUANG W，et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose，GLUT9，and URAT1[J]. Am J Physiol Renal Physiol，2019，316（1）：F173-185. DOI：10.1152/ajprenal.00462.2018.
[20]	程远磊，李飞. 尿酸转运蛋白的研究现状[J]. 湖北医药学院学报，2017，36（5）：470-473，486. DOI：10.13819/j.issn.1006-9674.2017.05.022.
[21]	DINOUR D，GRAY N K，CAMPBELL S，et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia[J]. J Am Soc Nephrol，2010，21（1）：64-72. DOI：10.1681/ASN.2009040406.
[22]	MANCIKOVA A，KRYLOV V，HURBA O，et al. Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2[J]. Clin Exp Nephrol，2016，20（4）：578-584. DOI：10.1007/s10157-015-1186-z.
[23]	XU X X，LI C H，ZHOU P，et al. Uric acid transporters hiding in the intestine[J]. Pharm Biol，2016，54（12）：3151-3155. DOI：10.1080/13880209.2016.1195847.
[24]	HAGOS Y，STEIN D，UGELE B，et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter[J]. J Am Soc Nephrol，2007，18（2）：430-439. DOI：10.1681/ASN.2006040415.
[25]	BAHN A，HAGOS Y，REUTER S，et al. Identification of a new urate and high affinity nicotinate transporter，hOAT10 （SLC22A13）[J]. J Biol Chem，2008，283（24）：16332-16341. DOI：10.1074/jbc.M800737200.
[26]	SAKIYAMA M，MATSUO H，SHIMIZU S，et al. A common variant of organic anion transporter 4 （OAT4/SLC22A11） gene is associated with renal underexcretion type gout[J]. Drug Metab Pharmacokinet，2014，29（2）：208-210. DOI：10.2133/dmpk.dmpk-13-nt-070.
[27]	CHUNG S，KIM G H. Urate transporters in the kidney: what clinicians need to know[J]. Electrolyte Blood Press，2021，19（1）：1-9. DOI：10.5049/EBP.2021.19.1.1.
[28]	MATSUO H，TAKADA T，ICHIDA K，et al. Common defects of ABCG2，a high-capacity urate exporter，cause gout: a function-based genetic analysis in a Japanese population[J]. Sci Transl Med，2009，1（5）：5ra11. DOI：10.1126/scitranslmed.3000237.
[29]	DOYLE L A，YANG W，ABRUZZO L V，et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci USA，1998，95（26）：15665-15670. DOI：10.1073/pnas.95.26.15665.
[30]	陈海青，周璇，王秀秀. 槲皮素治疗高尿酸血症的机制研究[J]. 光明中医，2019，34（9）：1340-1344. DOI：10.3969/j.issn.1003-8914.2019.09.015.
[31]	TOYODA Y，MAN ÍKOVÁ A，KRYLOV V，et al. Functional characterization of clinically-relevant rare variants in ABCG2 identified in a gout and hyperuricemia cohort[J]. Cells，2019，8（4）：363. DOI：10.3390/cells8040363.
[32]	FUJITA K，YAMADA H，IIJIMA M，et al. Electrochemical analysis of uric acid excretion to the intestinal lumen: effect of serum uric acid-lowering drugs and 5/6 nephrectomy on intestinal uric acid levels[J]. PLoS One，2019，14（12）：e0226918. DOI：10.1371/journal.pone.0226918.
[33]	KOMORI H，YAMADA K，TAMAI I. Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells[J]. Biochim Biophys Acta Biomembr，2018，1860（5）：973-980.
[34]	MATSUO H，ICHIDA K，TAKADA T，et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout[J]. Sci Rep，2013，3：2014. DOI：10.1038/srep02014.
[35]	MATSUO H，TSUNODA T，OOYAMA K，et al. Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2[J]. Sci Rep，2016，6：31003. DOI：10.1038/srep31003.
[36]	WOODWARD O M，KÖTTGEN A，CORESH J，et al. Identification of a urate transporter，ABCG2，with a common functional polymorphism causing gout[J]. Proc Natl Acad Sci USA，2009，106（25）：10338-10342. DOI：10.1073/pnas.0901249106.
[37]	NIGAM S K. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways，signaling，and disease[J]. Annu Rev Pharmacol Toxicol，2018，58：663-687. DOI：10.1146/annurev-pharmtox-010617-052713.
[38]	王传旭，周嘉宝，吴志远，等. 基于IL-1β探讨矢志方对高尿酸血症小鼠肾组织OAT1/3表达的影响[J]. 中国中医药信息杂志，2022，29（12）：70-75. DOI：10.19879/j.cnki.1005-5304.202203682.
[39]	NIGAM S K，BUSH K T，MARTOVETSKY G，et al. The organic anion transporter （OAT） family: a systems biology perspective[J]. Physiol Rev，2015，95（1）：83-123. DOI：10.1152/physrev.00025.2013.
[40]	LIU H C，JAMSHIDI N，CHEN Y C，et al. An organic anion transporter 1 （OAT1）-centered metabolic network[J]. J Biol Chem，2016，291（37）：19474-19486. DOI：10.1074/jbc.M116.745216.
[41]	YONG T Q，CHEN S D，XIE Y Z，et al. Hypouricemic effects of Armillaria mellea on hyperuricemic mice regulated through OAT1 and CNT2[J]. Am J Chin Med，2018，46（3）：585-599. DOI：10.1142/S0192415X18500301.
[42]	FAN Y Z，LIANG Z X，ZHANG J H，et al. Oral proteasomal inhibitors ixazomib，oprozomib，and delanzomib upregulate the function of organic anion transporter 3 （OAT3）: implications in OAT3-mediated drug-drug interactions[J]. Pharmaceutics，2021，13（3）：314. DOI：10.3390/pharmaceutics13030314.
[43]	DRAGOJEVI J，MIHALJEVI I，POPOVI M，et al. Zebrafish （Danio rerio） Oat1 and Oat3 transporters and their interaction with physiological compounds[J]. Comp Biochem Physiol B Biochem Mol Biol，2019，236：110309. DOI：10.1016/j.cbpb.2019.110309.
[44]	TRUONG D M，KALER G，KHANDELWAL A，et al. Multi-level analysis of organic anion transporters 1，3，and 6 reveals major differences in structural determinants of antiviral discrimination[J]. J Biol Chem，2008，283（13）：8654-8663. DOI：10.1074/jbc.M708615200.
[45]	WU W，BUSH K T，NIGAM S K. Key role for the organic anion transporters，OAT1 and OAT3，in the in vivo handling of uremic toxins and solutes[J]. Sci Rep，2017，7（1）：4939. DOI：10.1038/s41598-017-04949-2.
[46]	OTANI N，OUCHI M，HAYASHI K，et al. Roles of organic anion transporters （OATs） in renal proximal tubules and their localization[J]. Anat Sci Int，2017，92（2）：200-206. DOI：10.1007/s12565-016-0369-3.
[47]	SUN H L，WU Y W，BIAN H G，et al. Function of uric acid transporters and their inhibitors in hyperuricaemia[J]. Front Pharmacol，2021，12: 667753. DOI：10.3389/fphar.2021.667753.
[48]	VAN AUBEL R A M H，SMEETS P H E，PETERS J G P，et al. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP[J]. J Am Soc Nephrol，2002，13（3）：595-603. DOI：10.1681/ASN.V133595.
[49]	DONG Z，ZHOU J R，JIANG S，et al. Effects of multiple genetic loci on the pathogenesis from serum urate to gout[J]. Sci Rep，2017，7：43614. DOI：10.1038/srep43614.
[50]	TANNER C，BOOCOCK J，STAHL E A，et al. Population-specific resequencing associates the ATP-binding cassette subfamily C member 4 gene with gout in New Zealand māori and Pacific men[J]. Arthritis Rheumatol，2017，69（7）：1461-1469. DOI：10.1002/art.40110.
[51]	SLOT A J，MOLINSKI S V，COLE S P C. Mammalian multidrug-resistance proteins （MRPs）[J]. Essays Biochem，2011，50（1）：179-207. DOI：10.1042/bse0500179.
[52]	DING X D，LI M M，PENG C L，et al. Uric acid transporters BCRP and MRP4 involved in chickens uric acid excretion[J]. BMC Vet Res，2019，15（1）：180. DOI：10.1186/s12917-019-1886-9.
[53]	MERRIMAN T R，et al. Population heterogeneity in the genetic control of serum urate[J]. Semin Nephrol，2011，31（5）：420-425. DOI：10.1016/j.semnephrol.2011.08.005.
[54]	CHIBA T，MATSUO H，KAWAMURA Y，et al. NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout[J]. Arthritis Rheumatol，2015，67（1）：281-287. DOI：10.1002/art.38884.
[55]	JUTABHA P，ANZAI N，WEMPE M F，et al. Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule[J]. Nucleosides Nucleotides Nucleic Acids，2011，30（12）：1302-1311. DOI：10.1080/15257770.2011.616564.
[56]	SUN H L，WU Y W，BIAN H G，et al. Function of uric acid transporters and their inhibitors in hyperuricaemia[J]. Front Pharmacol，2021，12：667753. DOI：10.3389/fphar.2021.667753.
[57]	JUTABHA P，ANZAI N，KITAMURA K，et al. Human sodium phosphate transporter 4 （hNPT4/SLC17A3） as a common renal secretory pathway for drugs and urate[J]. J Biol Chem，2010，285（45）：35123-35132. DOI：10.1074/jbc.M110.121301.
[58]	RISTIC B，SIKDER M O F，BHUTIA Y D，et al. Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis[J]. J Asian J Pharm Sci，2020，15（2）：173-180. DOI：10.1016/j.ajps.2019.10.002.
[59]	LAU H S，WISEMAN R F. Effect of uric acid on riboflavine production by intestinal coliform bacteria[J]. J Bacteriol，1964，87（2）：337-340. DOI：10.1128/jb.87.2.337-340.1964.
[60]	YAMADA N，IWAMOTO C，KANO H，et al. Evaluation of purine utilization by Lactobacillus gasseri strains with potential to decrease the absorption of food-derived purines in the human intestine[J]. Nucleosides Nucleotides Nucleic Acids，2016，35（10-12）：670-676. DOI：10.1080/15257770.2015.1125000.
[61]	WU J W，WEI Z H，CHENG P，et al. Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis[J]. Theranostics，2020，10（23）：10665-10679. DOI：10.7150/thno.43528.
[62]	DEBOSCH B J，KLUTH O，FUJIWARA H，et al. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9[J]. Nat Commun，2014，5：4642. DOI：10.1038/ncomms5642.
[63]	LI Q R，LIN H，NIU Y F，et al. Mangiferin promotes intestinal elimination of uric acid by modulating intestinal transporters[J]. Eur J Pharmacol，2020，888：173490. DOI：10.1016/j.ejphar.2020.173490.
[64]	HALPERIN KUHNS V L，WOODWARD O M. Urate transport in health and disease[J]. Best Pract Res Clin Rheumatol，2021，35（4）：101717. DOI：10.1016/j.berh.2021.101717.
[65]	李秋睿，李玲，林华. 肠道尿酸排泄及相关转运体的研究进展[J]. 国际药学研究杂志，2019，46（4）：261-265. DOI：10.13220/j.cnki.jipr.2019.04.003.
[66]	SARKADI B，OZVEGY-LACZKA C，NÉMET K，et al. ABCG2 —a transporter for all seasons[J]. FEBS Lett，2004，567（1）：116-120. DOI：10.1016/j.febslet.2004.03.123.
[67]	CHEN M，LU X Y，LU C，et al. Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway[J]. Arthritis Res Ther，2018，20（1）：20. DOI：10.1186/s13075-018-1512-4.
[68]	MATSUO H，TSUNODA T，OOYAMA K，et al. Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2[J]. Sci Rep，2016，6：31003. DOI：10.1038/srep31003.
[69]	ICHIDA K，MATSUO H，TAKADA T，et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia[J]. Nat Commun，2012，3：764. DOI：10.1038/ncomms1756.
[70]	YANO H，TAMURA Y，KOBAYASHI K，et al. Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease[J]. Clin Exp Nephrol，2014，18（1）：50-55. DOI：10.1007/s10157-013-0806-8.
[71]	BHATNAGAR V，RICHARD E L，WU W，et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling[J]. Clin Kidney J，2016，9（3）：444-453. DOI：10.1093/ckj/sfw010.
[72]	MATSUO H，ICHIDA K，TAKADA T，et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout[J]. Sci Rep，2013，3：2014. DOI：10.1038/srep02014.
[73]	SHIBUI A，TSUNODA T，SEKI N，et al. Isolation and chromosomal mapping of a novel human gene showing homology to Na⁺/PO₄ cotransporter[J]. J Hum Genet，1999，44（3）：190-192. DOI：10.1007/s100380050140.
[74]	Togawa，Natsuko，et al. A Na⁺-phosphate cotransporter homologue （SLC17A4 protein） is an intestinal organic anion exporter[J]. Am J Physiol Cell Physiol，2012，302（11）：C1652-1660. DOI：10.1152/ajpcell.00015.2012.